|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ulcerative colitis显示文摘 | Ingrid Ordás Lars Eckmann Mark Talamini Daniel C Baumgart William J Sandborn | 2012 | The Lancet2012，，9853： | 5 |
| 2 | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer显示文摘Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase Ⅲ trial showing an improved outcome over gemcitabine, the combination of gemcitabine/nab-paclitaxel emerged as another standard first-line treatment. However, this treatment is also associated with more side effects. In addition, despite initial promising data on the predictive role of SPARClevels, recent studies showed that these levels are not associated with nab-paclitaxel efficacy. The choice to use this treatment over FOLFIRINOX is therefore a topic of debate, also because no validated biomarkers to guide FOLFIRINOX treatment are available. In the era of actionable mutations and target agents it would be desirable to identify molecular factors or biomarkers to predict response to therapy in order to maximize the efficacy of treatment and avoid useless toxic effects for non-responding patients. However, until today the milestone of treatment for pancreatic cancer remains chemotherapy combinations, without predictive or monitoring tools existing to optimize therapy. This review analyzes the state-of-the-art treatments, promises and limitations of targeted therapies, ongoing trials and future perspectives, including potential role of microR NAs as predictive biomarkers. | Chiara Caparello Laura L Meijer Ingrid Garajova Alfredo Falcone Tessa Y Le Large Niccola Funel Geert Kazemier Godefridus J Peters Enrico Vasile Elisa Giovannetti | 2016 | World Journal of Gastroenterology2016，22，31： | 4 |
| 3 | Ulcerative colitis显示文摘 | Ingrid Ordás Lars Eckmann Mark Talamini Daniel C Baumgart William J Sandborn | 2012 | 2012 (9853)2012，，9853： | 3 |
| 4 | Intravenous immune globulin suppresses angiogenesis in mice and humans显示文摘Human intravenous immune globulin(IVIg),a purified IgG fraction composed of~60%IgG1 and obtained from the pooled plasma of thousands of donors,is clinically used for a wide range of diseases.The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG(IgG)Fc regions.Recently,we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI,a high-affinity receptor for IgG1.Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases,namely,neovascular age-related macular degeneration,corneal neovascularization,colorectal cancer,fibrosarcoma and peripheral arterial ischemic disease.Angioinhibition was mediated by the Fc region of IVIg,required FcγRI and had similar potency in transgenic mice expressing human FcγRs.Finally,IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities.These data place IVIg,an agent approved by the US Food and Drug Administration,as a novel angioinhibitory drug in doses that are currently administered in the clinical setting.In addition,they raise the possibility of an unintended effect of IVIg on blood vessels. | Reo Yasuma Valeria Cicatiello Takeshi Mizutani Laura Tudisco Younghee Kim Valeria Tarallo Sasha Bogdanovich Yoshio Hirano Nagaraj Kerur Shengjian Li Tetsuhiro Yasuma Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Balamurali K Ambati Sevim Barbasso Helmers Ingrid E Lundberg Ondrej Viklicky Jeanette HW Leusen J Sjef Verbeek Bradley D Gelfand Ana Bastos-Carvalho Sandro De Falco Jayakrishna Ambati | 2016 | Signal Transduction and Targeted Therapy2016，1，1： | 3 |
| 5 | An α‐E‐catenin ( CTNNA1 ) mutation in hereditary diffuse gastric cancer显示文摘 | Ian J Majewski Irma Kluijt Annemieke Cats Thomas S Scerri Daphne Jong Roelof JC Kluin Samantha Hansford Frans BL Hogervorst Astrid J Bosma Ingrid Hofland Marcel Winter David Huntsman Jos Jonkers Melanie Bahlo René Bernards | 2013 | J. Pathol2013，，4： | 2 |
| 6 | The Role of Lifestyle Change in the Prevention and Treatment of NAFLD显示文摘 | Elena Centis Rebecca Marzocchi Alessandro Suppini Riccardo Dalle Grave Nicola Villanova Ingrid J Hickman Giulio Marchesini | 2013 | Current Pharmaceutical Design2013，，29： | 2 |
| 7 | Ulcerative colitis显示文摘 | Ingrid Ordás Lars Eckmann Mark Talamini Daniel C Baumgart William J Sandborn | 2012 | The Lancet . 2012 (9853)2012，，： | 2 |
| 8 | Ulcerative colitis显示文摘 | Ingrid Ordás Lars Eckmann Mark Talamini Daniel C Baumgart William J Sandborn | 2012 | The Lancet2012，，9853： | 2 |
| 9 | Structural Requirements of the Fructan-Lipid Interaction 显示文摘 | Ingrid J V J Albert van kuik Toon H E | 2003 | Biophysical Journal2003，84，： | 1 |
| 10 | Natural history of uterine polyps and leiomyomata显示文摘 | Deborah J DeWaay Craig H Syrop Ingrid E Nygaard William A Davis Bradley J Van Voorhis | 2002 | Obstetrics & Gynecology2002，，1： | 1 |
| 11 | Ulcerative colitis显示文摘 | Ingrid Ordás Lars Eckmann Mark Talamini Daniel C Baumgart William J Sandborn | 2012 | The Lancet2012，，9853： | 1 |
| 12 | Acute endophthalmitis following intravitreal triamcinolone acetonide injection显示文摘 | Darius M Moshfeghi Peter K Kaiser Ingrid U Scott Jonathan E Sears Matthew Benz Juan P Sinesterra Richard S Kaiser Sophie J Bakri Raj K Maturi Jonathan Belmont Paul M Beer Timothy G Murray Hugo Quiroz-Mercado William F Mieler | 2003 | American Journal of Ophthalmology2003，，5： | 1 |
| 13 | Treatment of venous thromboembolism with the oral thrombin inhibitor,ximelagatran显示文摘 | Harenberg J Ingrid J Tivadar F | 2002 | Isr Med Assoc J2002，4，11： | 1 |
| 14 | Long-term anatomic and visual acuity outcomes after initial anatomic success with macular hole surgery显示文摘 | Ingrid U Scott Alexei L Moraczewski William E Smiddy Harry W Flynn William J Feuer | 2003 | American Journal of Ophthalmology2003，，5： | 1 |
| 15 | Storage and drivers of organic carbon in forest soils of southeast Germany (Bavaria) – Implications for carbon sequestration显示文摘 | Martin Wiesmeier J?rg Prietzel Frauke Barthold Peter Sp?rlein Uwe Geu? Edzard Hangen Arthur Reischl Bernd Schilling Margit von Lützow Ingrid K?gel-Knabner | 2013 | Forest Ecology and Management2013，，： | 1 |
| 16 | Cephalometric features of filipions with angle class I occlusion according to the Munich analysis显示文摘 | Marian A Sevilla N Ingrid R J | 2004 | Angle Orthod2004，75，1： | 1 |
| 17 | Development of an enzyme-linked immunosorbent assay for the detection of the pyrethroid insecticide fenpropathrin 显示文摘 | Donald W S Shirley J G | 1998 | J Agric and Food Chemistry1998，46，： | 1 |
| 18 | RTX toxin genotypes and phenotypes in Actinobacillus pleuropueumoniae field strains显示文摘 | Marianne B Johannes F D B Ingrid M C A J | 1994 | Journal of Clinical Microbiology1994，32，11： | 1 |
| 19 | Effects of tillage on runoff and erosion patterns显示文摘 | Ingrid T Gerard G Victor J | 2001 | Soil & Tillage research2001，61，1： | 1 |
| 20 | Independent effects of diet and exercise training on fat oxidation in non-alcoholic fatty liver disease显示文摘AIM To investigate the independent effects of 6-mo of dietary energy restriction or exercise training on wholebody and hepatic fat oxidation of patients with nonalcoholic fatty liver disease(NAFLD).METHODS Participants were randomised into either circuit exercise training(EX;n = 13;3 h/wk without changes in dietary habits),or dietary energy restriction(ER) without changes in structured physical activity(ER;n = 8).Respiratory quotient(RQ) and whole-body fat oxidation rates(Fatox) were determined by indirect calorimetry under basal,insulin-stimulated and exercise conditions.Severity of disease and steatosis was determined by liver histology;hepatic Fatox was estimated from plasma β-hydroxybutyrate co.ncentrations;cardiorespiratory fitness was expressed as VO2 peak.Complete-case analysis was performed(EX:n = 10;ER:n = 6).RESULTS Hepatic steatosis and NAFLD activity score decreased with ER but not with EX.β-hydroxybutyrate concentrations increased significantly in response to ER(0.08 ± 0.02 mmol/L vs 0.12 ± 0.04 mmol/L,P = 0.03) but remained unchanged in response to EX(0.10 ± 0.03 mmol/L vs 0.11 ± 0.07 mmol/L,P = 0.39).Basal RQ decreased(P = 0.05) in response.to EX,while this change was not significant after ER(P = 0.38).VO_(2peak)(P < 0.001) and maximal Fa_(tox) during aerobic exercise(P = 0.03) improved with EX but not with ER(P > 0.05).The increase in β-hydroxybutyrate concentrations was correlated with the reduction in hepatic steatosis(r =-0.56,P = 0.04).CONCLUSION ER and EX lead to specific benefits on fat metabolism of patients with NAFLD.Increased hepatic Fat_(ox) in response to ER could be one mechanism through which the ER group achieved reduction in steatosis. | Ilaria Croci Nuala M Byrne Veronique S Chachay Andrew P Hills Andrew D Clouston Trisha M O'Moore-Sullivan Johannes B Prins Graeme A Macdonald Ingrid J Hickman | 2016 | World Journal of Hepatology2016，8，27： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员